pre-miRNA Information | |
---|---|
pre-miRNA | hsa-mir-4251 |
Genomic Coordinates | chr1: 3127975 - 3128035 |
Description | Homo sapiens miR-4251 stem-loop |
Comment | None |
RNA Secondary Structure |
Mature miRNA Information | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mature miRNA | hsa-miR-4251 | |||||||||||||||
Sequence | 35| CCUGAGAAAAGGGCCAA |51 | |||||||||||||||
Evidence | Experimental | |||||||||||||||
Experiments | SOLiD | |||||||||||||||
SNPs in miRNA |
|
|||||||||||||||
Putative Targets |
miRNA Expression profile | |
---|---|
Human miRNA Tissue Atlas | |
Circulating MicroRNA Expression Profiling |
Gene Information | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene Symbol | LDLR | ||||||||||||||||||||
Synonyms | FH, FHC, LDLCQ2 | ||||||||||||||||||||
Description | low density lipoprotein receptor | ||||||||||||||||||||
Transcript | NM_000527 | ||||||||||||||||||||
Expression | |||||||||||||||||||||
Putative miRNA Targets on LDLR | |||||||||||||||||||||
3'UTR of LDLR (miRNA target sites are highlighted) |
>LDLR|NM_000527|3'UTR 1 ACATCTGCCTGGAGTCCCGTCCCTGCCCAGAACCCTTCCTGAGACCTCGCCGGCCTTGTTTTATTCAAAGACAGAGAAGA 81 CCAAAGCATTGCCTGCCAGAGCTTTGTTTTATATATTTATTCATCTGGGAGGCAGAACAGGCTTCGGACAGTGCCCATGC 161 AATGGCTTGGGTTGGGATTTTGGTTTCTTCCTTTCCTCGTGAAGGATAAGAGAAACAGGCCCGGGGGGACCAGGATGACA 241 CCTCCATTTCTCTCCAGGAAGTTTTGAGTTTCTCTCCACCGTGACACAATCCTCAAACATGGAAGATGAAAGGGGAGGGG 321 ATGTCAGGCCCAGAGAAGCAAGTGGCTTTCAACACACAACAGCAGATGGCACCAACGGGACCCCCTGGCCCTGCCTCATC 401 CACCAATCTCTAAGCCAAACCCCTAAACTCAGGAGTCAACGTGTTTACCTCTTCTATGCAAGCCTTGCTAGACAGCCAGG 481 TTAGCCTTTGCCCTGTCACCCCCGAATCATGACCCACCCAGTGTCTTTCGAGGTGGGTTTGTACCTTCCTTAAGCCAGGA 561 AAGGGATTCATGGCGTCGGAAATGATCTGGCTGAATCCGTGGTGGCACCGAGACCAAACTCATTCACCAAATGATGCCAC 641 TTCCCAGAGGCAGAGCCTGAGTCACTGGTCACCCTTAATATTTATTAAGTGCCTGAGACACCCGGTTACCTTGGCCGTGA 721 GGACACGTGGCCTGCACCCAGGTGTGGCTGTCAGGACACCAGCCTGGTGCCCATCCTCCCGACCCCTACCCACTTCCATT 801 CCCGTGGTCTCCTTGCACTTTCTCAGTTCAGAGTTGTACACTGTGTACATTTGGCATTTGTGTTATTATTTTGCACTGTT 881 TTCTGTCGTGTGTGTTGGGATGGGATCCCAGGCCAGGGAAAGCCCGTGTCAATGAATGCCGGGGACAGAGAGGGGCAGGT 961 TGACCGGGACTTCAAAGCCGTGATCGTGAATATCGAGAACTGCCATTGTCGTCTTTATGTCCGCCCACCTAGTGCTTCCA 1041 CTTCTATGCAAATGCCTCCAAGCCATTCACTTCCCCAATCTTGTCGTTGATGGGTATGTGTTTAAAACATGCACGGTGAG 1121 GCCGGGCGCAGTGGCTCACGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGCGGGTGGATCATGAGGTCAGGAGATCGAG 1201 ACCATCCTGGCTAACACGTGAAACCCCGTCTCTACTAAAAATACAAAAAATTAGCCGGGCGTGGTGGCGGGCACCTGTAG 1281 TCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATGGTGTGAACCCGGGAAGCGGAGCTTGCAGTGAGCCGAGATTGCGCCA 1361 CTGCAGTCCGCAGTCTGGCCTGGGCGACAGAGCGAGACTCCGTCTCAAAAAAAAAAAACAAAAAAAAACCATGCATGGTG 1441 CATCAGCAGCCCATGGCCTCTGGCCAGGCATGGCGAGGCTGAGGTGGGAGGATGGTTTGAGCTCAGGCATTTGAGGCTGT 1521 CGTGAGCTATGATTATGCCACTGCTTTCCAGCCTGGGCAACATAGTAAGACCCCATCTCTTAAAAAATGAATTTGGCCAG 1601 ACACAGGTGCCTCACGCCTGTAATCCCAGCACTTTGGGAGGCTGAGCTGGATCACTTGAGTTCAGGAGTTGGAGACCAGG 1681 CCTGAGCAACAAAGCGAGATCCCATCTCTACAAAAACCAAAAAGTTAAAAATCAGCTGGGTACGGTGGCACGTGCCTGTG 1761 ATCCCAGCTACTTGGGAGGCTGAGGCAGGAGGATCGCCTGAGCCCAGGAGGTGGAGGTTGCAGTGAGCCATGATCGAGCC 1841 ACTGCACTCCAGCCTGGGCAACAGATGAAGACCCTATTTCAGAAATACAACTATAAAAAAATAAATAAATCCTCCAGTCT 1921 GGATCGTTTGACGGGACTTCAGGTTCTTTCTGAAATCGCCGTGTTACTGTTGCACTGATGTCCGGAGAGACAGTGACAGC 2001 CTCCGTCAGACTCCCGCGTGAAGATGTCACAAGGGATTGGCAATTGTCCCCAGGGACAAAACACTGTGTCCCCCCCAGTG 2081 CAGGGAACCGTGATAAGCCTTTCTGGTTTCGGAGCACGTAAATGCGTCCCTGTACAGATAGTGGGGATTTTTTGTTATGT 2161 TTGCACTTTGTATATTGGTTGAAACTGTTATCACTTATATATATATATATACACACATATATATAAAATCTATTTATTTT 2241 TGCAAACCCTGGTTGCTGTATTTGTTCAGTGACTATTCTCGGGGCCCTGTGTAGGGGGTTATTGCCTCTGAAATGCCTCT 2321 TCTTTATGTACAAAGATTATTTGCACGAACTGGACTGTGTGCAACGCTTTTTGGGAGAATGATGTCCCCGTTGTATGTAT 2401 GAGTGGCTTCTGGGAGATGGGTGTCACTTTTTAAACCACTGTATAGAAGGTTTTTGTAGCCTGAATGTCTTACTGTGATC 2481 AATTAAATTTCTTAAATGAACCAATTTGTCTAAAAAAAAAAA Target sites
Provided by authors
Predicted by miRanda
DRVs
SNPs
DRVs & SNPs
|
||||||||||||||||||||
miRNA-target interactions (Predicted by miRanda) |
|
||||||||||||||||||||
DRVs in gene 3'UTRs | |||||||||||||||||||||
SNPs in gene 3'UTRs |
Experimental Support 1 for Functional miRNA-Target Interaction | |||||||
---|---|---|---|---|---|---|---|
miRNA:Target | ---- | ||||||
Validation Method |
|
||||||
Conditions | HEK293 | ||||||
Location of target site | 3'UTR | ||||||
Tools used in this research | TargetScan , miRTarCLIP , Piranha | ||||||
Original Description (Extracted from the article) |
...
PAR-CLIP data was present in GSM545216. RNA binding protein: AGO2. Condition:miR-124 transfection
... - Hafner M; Landthaler M; Burger L; Khorshid et al., 2010, Cell. |
||||||
miRNA-target interactions (Provided by authors) |
|
||||||
Article |
- Hafner M; Landthaler M; Burger L; Khorshid et al. - Cell, 2010
RNA transcripts are subject to posttranscriptional gene regulation involving hundreds of RNA-binding proteins (RBPs) and microRNA-containing ribonucleoprotein complexes (miRNPs) expressed in a cell-type dependent fashion. We developed a cell-based crosslinking approach to determine at high resolution and transcriptome-wide the binding sites of cellular RBPs and miRNPs. The crosslinked sites are revealed by thymidine to cytidine transitions in the cDNAs prepared from immunopurified RNPs of 4-thiouridine-treated cells. We determined the binding sites and regulatory consequences for several intensely studied RBPs and miRNPs, including PUM2, QKI, IGF2BP1-3, AGO/EIF2C1-4 and TNRC6A-C. Our study revealed that these factors bind thousands of sites containing defined sequence motifs and have distinct preferences for exonic versus intronic or coding versus untranslated transcript regions. The precise mapping of binding sites across the transcriptome will be critical to the interpretation of the rapidly emerging data on genetic variation between individuals and how these variations contribute to complex genetic diseases.
LinkOut: [PMID: 20371350]
|
Experimental Support 2 for Functional miRNA-Target Interaction | |||||||
---|---|---|---|---|---|---|---|
miRNA:Target | ---- | ||||||
Validation Method |
|
||||||
Conditions | TZM-bl | ||||||
Location of target site | 3'UTR | ||||||
Tools used in this research | TargetScan , miRTarCLIP , Piranha | ||||||
Original Description (Extracted from the article) |
...
PAR-CLIP data was present in GSM1462573. RNA binding protein: AGO2. Condition:TZM-bl BaL
... - Whisnant AW; Bogerd HP; Flores O; Ho P; et al., 2013, mBio. |
||||||
miRNA-target interactions (Provided by authors) |
|
||||||
Article |
- Whisnant AW; Bogerd HP; Flores O; Ho P; et al. - mBio, 2013
UNLABELLED: The question of how HIV-1 interfaces with cellular microRNA (miRNA) biogenesis and effector mechanisms has been highly controversial. Here, we first used deep sequencing of small RNAs present in two different infected cell lines (TZM-bl and C8166) and two types of primary human cells (CD4(+) peripheral blood mononuclear cells [PBMCs] and macrophages) to unequivocally demonstrate that HIV-1 does not encode any viral miRNAs. Perhaps surprisingly, we also observed that infection of T cells by HIV-1 has only a modest effect on the expression of cellular miRNAs at early times after infection. Comprehensive analysis of miRNA binding to the HIV-1 genome using the photoactivatable ribonucleoside-induced cross-linking and immunoprecipitation (PAR-CLIP) technique revealed several binding sites for cellular miRNAs, a subset of which were shown to be capable of mediating miRNA-mediated repression of gene expression. However, the main finding from this analysis is that HIV-1 transcripts are largely refractory to miRNA binding, most probably due to extensive viral RNA secondary structure. Together, these data demonstrate that HIV-1 neither encodes viral miRNAs nor strongly influences cellular miRNA expression, at least early after infection, and imply that HIV-1 transcripts have evolved to avoid inhibition by preexisting cellular miRNAs by adopting extensive RNA secondary structures that occlude most potential miRNA binding sites. IMPORTANCE: MicroRNAs (miRNAs) are a ubiquitous class of small regulatory RNAs that serve as posttranscriptional regulators of gene expression. Previous work has suggested that HIV-1 might subvert the function of the cellular miRNA machinery by expressing viral miRNAs or by dramatically altering the level of cellular miRNA expression. Using very sensitive approaches, we now demonstrate that neither of these ideas is in fact correct. Moreover, HIV-1 transcripts appear to largely avoid regulation by cellular miRNAs by adopting an extensive RNA secondary structure that occludes the ability of cellular miRNAs to interact with viral mRNAs. Together, these data suggest that HIV-1, rather than seeking to control miRNA function in infected cells, has instead evolved a mechanism to become largely invisible to cellular miRNA effector mechanisms.
LinkOut: [PMID: 23592263]
|
Experimental Support 3 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Conditions | MCF7 |
Location of target site | 3'UTR |
Tools used in this research | TargetScan , miRTarCLIP , Piranha |
Original Description (Extracted from the article) |
...
PAR-CLIP data was present in SRR1045082. RNA binding protein: AGO2. Condition:Untreated
... - Farazi TA; Ten Hoeve JJ; Brown M; et al., 2014, Genome biology. |
Article |
- Farazi TA; Ten Hoeve JJ; Brown M; et al. - Genome biology, 2014
BACKGROUND: Various microRNAs (miRNAs) are up- or downregulated in tumors. However, the repression of cognate miRNA targets responsible for the phenotypic effects of this dysregulation in patients remains largely unexplored. To define miRNA targets and associated pathways, together with their relationship to outcome in breast cancer, we integrated patient-paired miRNA-mRNA expression data with a set of validated miRNA targets and pathway inference. RESULTS: To generate a biochemically-validated set of miRNA-binding sites, we performed argonaute-2 photoactivatable-ribonucleoside-enhanced crosslinking and immunoprecipitation (AGO2-PAR-CLIP) in MCF7 cells. We then defined putative miRNA-target interactions using a computational model, which ranked and selected additional TargetScan-predicted interactions based on features of our AGO2-PAR-CLIP binding-site data. We subselected modeled interactions according to the abundance of their constituent miRNA and mRNA transcripts in tumors, and we took advantage of the variability of miRNA expression within molecular subtypes to detect miRNA repression. Interestingly, our data suggest that miRNA families control subtype-specific pathways; for example, miR-17, miR-19a, miR-25, and miR-200b show high miRNA regulatory activity in the triple-negative, basal-like subtype, whereas miR-22 and miR-24 do so in the HER2 subtype. An independent dataset validated our findings for miR-17 and miR-25, and showed a correlation between the expression levels of miR-182 targets and overall patient survival. Pathway analysis associated miR-17, miR-19a, and miR-200b with leukocyte transendothelial migration. CONCLUSIONS: We combined PAR-CLIP data with patient expression data to predict regulatory miRNAs, revealing potential therapeutic targets and prognostic markers in breast cancer.
LinkOut: [PMID: 24398324]
|
CLIP-seq Support 1 for dataset GSM4903833 | |
---|---|
Method / RBP | HITS-CLIP / AGO |
Cell line / Condition | Dermal fibroblasts / CTL_TD_21_a |
Location of target site | NM_000527 | 3UTR | CCUGGUGCCCAUCCUCCCGACCCCUACCCACUUCCAUUCCCGUGGUCUCCUUGCACUUUCUCAGUUCAGAGUUGUACACUGUGUACAUUUGGCAUUUGUGUUAUUAUUUUGCACUGUUUUCUGUCGUGUGUGUUGGGAUGGGAUCCCAGGCCAGGGAAAGCCC |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Accession Series | GSE161239 |
CLIP-seq Viewer | Link |
CLIP-seq Support 2 for dataset GSM4903834 | |
---|---|
Method / RBP | HITS-CLIP / AGO |
Cell line / Condition | Dermal fibroblasts / CTL_TD_21_b |
Location of target site | NM_001195798 | 3UTR | AGCCUGGUGCCCAUCCUCCCGACCCCUACCCACUUCCAUUCCCGUGGUCUCCUUGCACUUUCUCAGUUCAGAGUUGUACACUGUGUACAUUUGGCAUUUGUGUUAUUAUUUUGCACUGUUUUCUGUCGUGUGUGUUGGGAUGGGAUCCCAGGCCAGGGAAAGCCC |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Accession Series | GSE161239 |
CLIP-seq Viewer | Link |
CLIP-seq Support 3 for dataset GSM4903837 | |
---|---|
Method / RBP | HITS-CLIP / AGO |
Cell line / Condition | Dermal fibroblasts / 124_TD_21_b |
Location of target site | NM_000527 | 3UTR | UCCUCCCGACCCCUACCCACUUCCAUUCCCGUGGUCUCCUUGCACUUUCUCAGUUCAGAGUUGUACACUGUGUACAUUUGGCAUUUGUGUUAUUAUUUUGCACUGUUUUCUGUCGUGUGUGUUGGGAUGGGAUCCCAGGCCAGGGAAAGCCC |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Accession Series | GSE161239 |
CLIP-seq Viewer | Link |
CLIP-seq Support 4 for dataset GSM545216 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | HEK293 / miR-124 transfection |
Location of target site | ENST00000558518.1 | 3UTR | UCUCCUUGCACUUUCUCAG |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 20371350 / GSE21578 |
CLIP-seq Viewer | Link |
CLIP-seq Support 5 for dataset SRR1045082 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | MCF7 / Untreated |
Location of target site | ENST00000558518.1 | 3UTR | UCUCCUUGCACUUUCUCAG |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 24398324 / SRX388831 |
CLIP-seq Viewer | Link |
CLIP-seq Support 6 for dataset GSM1462573 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | TZM-bl / TZM-bl BaL |
Location of target site | ENST00000558518.1 | 3UTR | UGGUCUCCUUGCACUUUCUCAG |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 23592263 / GSE59944 |
CLIP-seq Viewer | Link |
MiRNA-Target Expression Profile | |||||||
---|---|---|---|---|---|---|---|
|
MiRNA-Target Expression Profile (TCGA) | |||||||
---|---|---|---|---|---|---|---|
|
98 hsa-miR-4251 Target Genes:
Functional analysis:
ID | Target | Description | Validation methods | |||||||||
Strong evidence | Less strong evidence | |||||||||||
MIRT056156 | OTUD1 | OTU deubiquitinase 1 | 2 | 2 | ||||||||
MIRT080004 | MYL12B | myosin light chain 12B | 2 | 2 | ||||||||
MIRT080407 | ONECUT2 | one cut homeobox 2 | 2 | 2 | ||||||||
MIRT081901 | KCTD15 | potassium channel tetramerization domain containing 15 | 2 | 2 | ||||||||
MIRT090342 | SEC61A1 | Sec61 translocon alpha 1 subunit | 2 | 8 | ||||||||
MIRT096824 | ZSWIM6 | zinc finger SWIM-type containing 6 | 2 | 4 | ||||||||
MIRT140185 | CHAC1 | ChaC glutathione specific gamma-glutamylcyclotransferase 1 | 2 | 2 | ||||||||
MIRT149716 | LDLR | low density lipoprotein receptor | 2 | 6 | ||||||||
MIRT205293 | STK11IP | serine/threonine kinase 11 interacting protein | 2 | 2 | ||||||||
MIRT213265 | REST | RE1 silencing transcription factor | 2 | 6 | ||||||||
MIRT254069 | BACH1 | BTB domain and CNC homolog 1 | 2 | 2 | ||||||||
MIRT256251 | ANKRD33B | ankyrin repeat domain 33B | 2 | 2 | ||||||||
MIRT264966 | TMEM136 | transmembrane protein 136 | 2 | 2 | ||||||||
MIRT267496 | FEN1 | flap structure-specific endonuclease 1 | 2 | 2 | ||||||||
MIRT285077 | MIER1 | MIER1 transcriptional regulator | 2 | 2 | ||||||||
MIRT296167 | NCOA3 | nuclear receptor coactivator 3 | 2 | 2 | ||||||||
MIRT316073 | ABRACL | ABRA C-terminal like | 2 | 2 | ||||||||
MIRT360286 | HIST1H3E | histone cluster 1 H3 family member e | 2 | 2 | ||||||||
MIRT364793 | PRRC2B | proline rich coiled-coil 2B | 2 | 2 | ||||||||
MIRT443277 | TSPAN15 | tetraspanin 15 | 2 | 2 | ||||||||
MIRT443453 | CLIC5 | chloride intracellular channel 5 | 2 | 2 | ||||||||
MIRT445938 | KLHL32 | kelch like family member 32 | 2 | 2 | ||||||||
MIRT448012 | HLA-DOA | major histocompatibility complex, class II, DO alpha | 2 | 2 | ||||||||
MIRT448382 | TP53INP1 | tumor protein p53 inducible nuclear protein 1 | 2 | 4 | ||||||||
MIRT448499 | RYBP | RING1 and YY1 binding protein | 2 | 2 | ||||||||
MIRT449896 | C11orf34 | placenta expressed transcript 1 | 1 | 2 | ||||||||
MIRT450457 | ZDHHC2 | zinc finger DHHC-type containing 2 | 2 | 2 | ||||||||
MIRT450849 | HTR2A | 5-hydroxytryptamine receptor 2A | 2 | 2 | ||||||||
MIRT453774 | NUCB1 | nucleobindin 1 | 2 | 10 | ||||||||
MIRT464399 | URM1 | ubiquitin related modifier 1 | 2 | 2 | ||||||||
MIRT465008 | TUBB2A | tubulin beta 2A class IIa | 2 | 8 | ||||||||
MIRT465145 | TSC22D2 | TSC22 domain family member 2 | 2 | 2 | ||||||||
MIRT467799 | SLC2A14 | solute carrier family 2 member 14 | 2 | 2 | ||||||||
MIRT472597 | NACC1 | nucleus accumbens associated 1 | 2 | 2 | ||||||||
MIRT477969 | DPM2 | dolichyl-phosphate mannosyltransferase subunit 2, regulatory | 2 | 2 | ||||||||
MIRT486586 | ZNF619 | zinc finger protein 619 | 2 | 2 | ||||||||
MIRT487739 | MICAL2 | microtubule associated monooxygenase, calponin and LIM domain containing 2 | 2 | 4 | ||||||||
MIRT492529 | PTMA | prothymosin, alpha | 2 | 6 | ||||||||
MIRT496845 | KCNIP2 | potassium voltage-gated channel interacting protein 2 | 2 | 2 | ||||||||
MIRT499064 | CTBP1 | C-terminal binding protein 1 | 2 | 4 | ||||||||
MIRT502046 | LAMTOR1 | late endosomal/lysosomal adaptor, MAPK and MTOR activator 1 | 2 | 6 | ||||||||
MIRT503907 | ZSCAN25 | zinc finger and SCAN domain containing 25 | 2 | 2 | ||||||||
MIRT506776 | KLHL15 | kelch like family member 15 | 2 | 4 | ||||||||
MIRT510003 | UCP1 | uncoupling protein 1 | 2 | 6 | ||||||||
MIRT513040 | BRIX1 | BRX1, biogenesis of ribosomes | 2 | 2 | ||||||||
MIRT513174 | MOAP1 | modulator of apoptosis 1 | 2 | 6 | ||||||||
MIRT517592 | ZNF579 | zinc finger protein 579 | 2 | 4 | ||||||||
MIRT521825 | POLR1D | RNA polymerase I subunit D | 2 | 2 | ||||||||
MIRT530663 | TRIM56 | tripartite motif containing 56 | 2 | 2 | ||||||||
MIRT531718 | TARS | threonyl-tRNA synthetase | 2 | 2 | ||||||||
MIRT535154 | PLEKHG5 | pleckstrin homology and RhoGEF domain containing G5 | 2 | 2 | ||||||||
MIRT536385 | LEFTY1 | left-right determination factor 1 | 2 | 2 | ||||||||
MIRT543847 | APIP | APAF1 interacting protein | 2 | 2 | ||||||||
MIRT546973 | PRKAB2 | protein kinase AMP-activated non-catalytic subunit beta 2 | 2 | 2 | ||||||||
MIRT548667 | CSRNP3 | cysteine and serine rich nuclear protein 3 | 2 | 2 | ||||||||
MIRT548799 | CLIP4 | CAP-Gly domain containing linker protein family member 4 | 2 | 4 | ||||||||
MIRT549610 | TMEM101 | transmembrane protein 101 | 2 | 2 | ||||||||
MIRT549716 | NUP37 | nucleoporin 37 | 2 | 4 | ||||||||
MIRT549873 | ZNF260 | zinc finger protein 260 | 2 | 2 | ||||||||
MIRT555383 | PPP1CC | protein phosphatase 1 catalytic subunit gamma | 2 | 2 | ||||||||
MIRT566976 | LBR | lamin B receptor | 2 | 2 | ||||||||
MIRT568052 | CHSY1 | chondroitin sulfate synthase 1 | 2 | 2 | ||||||||
MIRT570970 | TMBIM4 | transmembrane BAX inhibitor motif containing 4 | 2 | 2 | ||||||||
MIRT571174 | ZNF85 | zinc finger protein 85 | 2 | 2 | ||||||||
MIRT571364 | ZNF45 | zinc finger protein 45 | 2 | 2 | ||||||||
MIRT572309 | LSM4 | LSM4 homolog, U6 small nuclear RNA and mRNA degradation associated | 2 | 2 | ||||||||
MIRT572493 | BTN2A2 | butyrophilin subfamily 2 member A2 | 2 | 2 | ||||||||
MIRT606783 | KIAA0040 | KIAA0040 | 2 | 5 | ||||||||
MIRT607952 | NFAM1 | NFAT activating protein with ITAM motif 1 | 2 | 10 | ||||||||
MIRT609978 | HERPUD2 | HERPUD family member 2 | 2 | 2 | ||||||||
MIRT610069 | CD300E | CD300e molecule | 2 | 2 | ||||||||
MIRT610118 | IL17REL | interleukin 17 receptor E like | 2 | 2 | ||||||||
MIRT610151 | PRMT8 | protein arginine methyltransferase 8 | 2 | 4 | ||||||||
MIRT611075 | ZNF621 | zinc finger protein 621 | 2 | 2 | ||||||||
MIRT612011 | COX17 | COX17, cytochrome c oxidase copper chaperone | 2 | 2 | ||||||||
MIRT617901 | PTCHD3 | patched domain containing 3 | 2 | 2 | ||||||||
MIRT618052 | MRVI1 | murine retrovirus integration site 1 homolog | 2 | 2 | ||||||||
MIRT619526 | ZNF74 | zinc finger protein 74 | 2 | 2 | ||||||||
MIRT624276 | CRISPLD2 | cysteine rich secretory protein LCCL domain containing 2 | 2 | 2 | ||||||||
MIRT625357 | MGLL | monoglyceride lipase | 2 | 2 | ||||||||
MIRT626756 | NDUFA9 | NADH:ubiquinone oxidoreductase subunit A9 | 2 | 2 | ||||||||
MIRT628851 | FAM151B | family with sequence similarity 151 member B | 2 | 2 | ||||||||
MIRT630458 | GMPS | guanine monophosphate synthase | 2 | 2 | ||||||||
MIRT634536 | MRPS17 | mitochondrial ribosomal protein S17 | 2 | 2 | ||||||||
MIRT638806 | DCTN3 | dynactin subunit 3 | 2 | 2 | ||||||||
MIRT647607 | TMTC2 | transmembrane and tetratricopeptide repeat containing 2 | 2 | 2 | ||||||||
MIRT650885 | PPP1R15A | protein phosphatase 1 regulatory subunit 15A | 2 | 2 | ||||||||
MIRT653507 | SLC43A2 | solute carrier family 43 member 2 | 2 | 2 | ||||||||
MIRT658608 | ENTPD5 | ectonucleoside triphosphate diphosphohydrolase 5 | 2 | 2 | ||||||||
MIRT666345 | SKAP2 | src kinase associated phosphoprotein 2 | 2 | 2 | ||||||||
MIRT693743 | ACACA | acetyl-CoA carboxylase alpha | 2 | 2 | ||||||||
MIRT704049 | EDEM3 | ER degradation enhancing alpha-mannosidase like protein 3 | 2 | 2 | ||||||||
MIRT709789 | CYBRD1 | cytochrome b reductase 1 | 2 | 2 | ||||||||
MIRT711837 | AMOTL2 | angiomotin like 2 | 2 | 2 | ||||||||
MIRT711875 | VASP | vasodilator stimulated phosphoprotein | 2 | 2 | ||||||||
MIRT717349 | RAB40A | RAB40A, member RAS oncogene family | 2 | 2 | ||||||||
MIRT717746 | MYLK | myosin light chain kinase | 2 | 2 | ||||||||
MIRT725398 | LRIG2 | leucine rich repeats and immunoglobulin like domains 2 | 2 | 2 |
miRNA-Drug Associations | ||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
miRNA-Drug Resistance Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|